Summary of Recommendations
This guidance is intended for the International Organization for Migration (IOM) physicians and other panel physicians who administer overseas predeparture presumptive treatment for intestinal parasites, but may also be referenced by U.S. medical providers caring for refugees who will be receiving presumptive treatment after they arrive in the United States.
While these recommendations have been implemented in many overseas sites, logistical and procurement issues still limit their full implementation in some. All Middle Eastern, Asian, North African, Latin American, and Caribbean refugees should receive presumptive therapy with:
This guidance is intended for the International Organization for Migration (IOM) physicians and other panel physicians who administer overseas predeparture presumptive treatment for intestinal parasites, but may also be referenced by U.S. medical providers caring for refugees who will be receiving presumptive treatment after they arrive in the United States.
While these recommendations have been implemented in many overseas sites, logistical and procurement issues still limit their full implementation in some. All Middle Eastern, Asian, North African, Latin American, and Caribbean refugees should receive presumptive therapy with:
- All Middle Eastern, Asian, North African, Latin American, and Caribbean refugees should receive presumptive therapy with:
- Albendazole, single dose of 400 mg (200 mg for children 12-23 months)
AND - Ivermectin, two doses 200 mcg/Kg orally once a day for 2 days before departure to the United States.
- Overseas Refugee Health Guidance | Immigrant and Refugee Health | CDC
- Albendazole, single dose of 400 mg (200 mg for children 12-23 months)